NCT03810833View on ClinicalTrials.gov

Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

September 23, 2019

Study Completion Date

September 23, 2019

Conditions
Acute Kidney Injury
Interventions
DEVICE

Brilliance device sensor

Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.

Trial Locations (1)

63141

St. Louis Clinical Trials, St Louis

Sponsors

Lead Sponsor

MediBeacon
All Listed Sponsors
lead

MediBeacon

INDUSTRY

NCT03810833 - Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System | Biotech Hunter | Biotech Hunter